Successful treatment of a COVID-19 patient with thrombotic microangiopathy

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may cause acute kidney injury and thrombosis in patients with coronavirus disease 2019 (COVID-19) [1]. Postmortem studies have shown venous thromboembolism in addition to thrombotic microangiopathy (TMA), endothelial swelling and diffuse microvascular thrombosis consistent with complement fragment deposits in the endothelium [2]. Also, the complement system plays a central role in the pathology of TMA. The successful use of complement inhibitors in a COVID-19 patient with TMA has not been reported previously. In this report we present a COVID-19 patient with TMA who was treated with eculizumab.